Public Health | November 19, 2021
CIMS multi super specialty hospital performs 150 bone marrow transplants
The Ahmedabad based hospital in association with Sankalp India Foundation had established the BMT unit in 2017
The Ahmedabad based hospital in association with Sankalp India Foundation had established the BMT unit in 2017
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
Subscribe To Our Newsletter & Stay Updated
